Homeopathy for cancer

Homeopathy for cancer treatment is a new subject that never been evaluated because the majority of scientists do not understand and do not believe in homeopathy in general.

The following material published at the National Library of Medicine by The National Center for Biotechnology Information

The clinical studies showed the effectiveness of the use of homeopathic remedies for cancer

This clinical study was carried out in four outpatient centers using different forms of homeopathy for cancer patients:

• Otto Wagner Hospital, Department of Pulmonology I, Vienna, Austria;
• Lienz Hospital, Department of Medicine, Tyrol;
• Vienna University of Medicine (Vienna General Hospital), Department of Medicine I, Division of Oncology;
• Elisabethinenspital, Department of Medicine, Linz, Austria.

This study described in this article was published in a respected mainstream cancer journal called The Oncologist which is the official journal of the European Society of Oncologists.

In 2020, a randomized, prospective, double-blind, placebo-controlled, three-arm, multicenter, phase III clinical study evaluated the probable effects of additive homeopathic remedies for cancer compared to placebo in a group of women that suffer from advanced stage IV non-small cell lung (NSCLC) breast cancer, with respect to the quality of life (QoL) in the two randomized groups and survival time in all three groups (Frass, Gründling, Lechleitner, et al, 2020).

The clinical trial rules

The following rules were implemented during this clinical study.

The group of patients selected for the study visited the university teaching hospital every 9 weeks: 150 patients with stage IV NSCLC were included in the study; 98 received individualized homeopathic remedies (n = 51) or double-blind placebo (n = 47), and 52 control patients without homeopathic cancer treatment were observed for survival only. The control group (the third group) were patients who refused to participate in the randomized trial but agreed to observe the course of their disease without any homeopathic cancer treatment intervention.

The study showed that QoL and functional and symptomatic scales disclosed significant improvement in the homeopathy group compared to placebo after 9 and 18 weeks of homeopathic cancer treatment (p <0.001). The median survival time was significantly longer in the homeopathy group (435 days) compared to placebo (257 days; p = 0.010), and also compared to the control group (228 days; p <0.001). The survival rate in the homeopathy group was significantly different from the placebo (p = 0.020) and from the control (p <0.001). Symptoms (nausea, dyspnea, loss of appetite, etc.) were also rated significantly better in the homeopathy group.

In line with the best clinical research standards, this level of research is top-notch (RCT, multicenter, three-arm, 150 patients).

All homeopathic prescriptions began with Q1 dilutions (also called LM potencies) of the selected drugs for 3 weeks and continued in ascending order of Q2, Q3 of the same agent or selected alternative (3 weeks each) to Q30. Where the test substance was changed for any reason, a new cycle started from the beginning of Q1. The main reason for changing the test substance was the deterioration of the disease state.

The researchers concluded that homeopathy for cancer not only positively influences QoL but also survival rate and that further research involving other neoplastic entities is warranted.

NOTE: Lung cancer is the second most common cancer in men and women, as well as the leading cause of cancer-related mortality in the United States _0_, accounting for 29% of all cancer-related mortality in men and 26% of those in women _1_. More than 85% of lung cancers are non-small cell lung cancer (NSCLC) _2_, for which surgery is the preferred therapy in the early stages. Unfortunately, most patients are diagnosed in stage III or IV, by which time NSCLC is inoperable _3_. Chemotherapy is the standard treatment for unresectable NSCLC _4_, but its adverse reactions often prevent completion of the recommended number of courses _5_. Therefore, additional approaches are warranted to reduce the toxicity of chemotherapy and improve their clinical efficacy.

“Non-small cell lung cancer” is a group of lung cancers that behave in a similar way, such as squamous cell carcinoma and adenocarcinoma. Symptoms are a persistent cough, shortness of breath, weight loss, or coughing up blood. Treatments typically include surgery, chemotherapy, and radiation therapy. The 5-year survival rate for non-small cell lung cancer is 24%, compared with 6% for small cell lung cancer.

Related researches, studies, and clinical trials about homeopathy for cancer.

Similar information presented in the report provided by Moshe A Frenkel from the University of Texas MD And犀利士
erson Cancer Center by ResearchGate.

Moshe A Frenkel mentioned in his post: “The figures from a few groups that researched homeopathic treatment of different cancer models confirmed the beneficial outcome of healing using homeopathic remedies for cancer.”

Another study performed at the Medical University of Vienna concluded:

Current results suggest a confident and encouraging influence of homeopathic remedies for cancer on comprehensive health and well-being in cancer patients.

Homeopathy for cancer in Philadelphia

At the Philadelphia Homeopathic Clinic, we believe that homeopathy is a great add-on method of treatment for all kinds of cancers. We do not recommend, however, to use Homeopathy for cancer as the main approach.

If you need an evaluation appointment with Dr. Victor Tsan, contact our clinic (267) 403-3085 or use our online scheduling application

REFERENCE:

Lechleitner P, Frass M, Pirker C, Gründling C, Domayer J, Grasmuk-Siegl E, Hochmayr M, Schrott A, Gaertner K, Duscheck C, Muchitsch I, Marosi C, Schumacher M, Zöchbauer-Müller S, Manchanda RK, Burghuber O. Homeopathic Treatment as an ‘Add on’ Therapy May Improve Quality of Life and Prolong Survival in Patients with Non-Small Cell Lung Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Three-Arm, Multicenter Study. Oncologist. 2020 Oct 3. doi: 10.1002/onco.13548. Epub ahead of print. PMID: 33010094.